Arpida superbug drug benefits confirmed in trial

(Reuters) - The Phase III trials were designed to compare the efficacy
and safety of iclaprim in the treatment of skin infections with
that of market leader linezolid, marketed by Pfizer as Zyvox.




"The pre-specified primary efficacy endpoint of statistical
non-inferiority in the clinical cure rate at the Test-Of-Cure
visit was achieved," Arpida said.


Read more at Reuters.com Government Filings News

CORRECTED - Moody's weighs ratings as drug-patent lapses near

(Reuters) - NEW YORK, July 10 - Moody's Investors Service on
Tuesday said a wave of patent expirations on blockbuster drugs
between 2010 and 2012 could lead it to begin lowering its
credit ratings on a number of large U.S. drugmakers several
years before then.




Eli Lilly and Co. , Pfizer Inc. and
Bristol-Myers Squibb Co. are particularly vulnerable to
the downgrades because the top-selling drug of each expires in
that period.


Read more at Reuters.com Bonds News

Moody's weighs ratings as drug-patent lapses near

(Reuters) - Eli Lilly and Co. , Pfizer Inc. and
Bristol-Myers Squibb Co. are particularly vulnerable to
the downgrades because the top-selling drug of each expires in
that period.




Merck & Co. could also be adversely affected as two
of its important drugs face patent expirations.


Read more at Reuters.com Government Filings News

Europe approves once-daily Cialis for impotence

(Reuters) - The drug's maker, Eli Lilly and Co. , said on Monday that the green light from the European Commission meant Cialis was the first erectile dysfunction medicine cleared for continuous use.



Until now, drugs such as Cialis and Pfizer Inc.'s rival product, Viagra, have been taken as needed.


Read more at Reuters.com Government Filings News